The role of α7 nicotinic acetylcholine receptors and α7-specific antibodies in neuroinflammation related to alzheimer disease

Current Pharmaceutical Design

Volumn 22, Issue 14, 2016, Pages 2035-2049

  Skok, Maryna ^a   Lykhmus, Olena ^a  

^a PALLADIN INSTITUTE OF BIOCHEMISTRY   (Ukraine)

Author keywords

Alzheimer disease; Antibody; Inflammation; Nicotinic acetylcholine receptor

Indexed keywords

ALPHA7 ANTIBODY; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AUTOANTIBODY; BUNGAROTOXIN RECEPTOR; INTERLEUKIN 6; UNCLASSIFIED DRUG; ANTIBODY;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; ASTROCYTE; BRAIN CELL; CELL SURVIVAL; CELL VIABILITY; CHOLINERGIC NERVE CELL; COMPREHENSION; DISEASE COURSE; DOWN REGULATION; EPISODIC MEMORY; GLIA CELL; GLIOBLASTOMA CELL LINE; HUMAN; LANGUAGE; LEARNING; MEMORY DISORDER; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; ORIENTATION; PRIORITY JOURNAL; THINKING; ANIMAL; INFLAMMATION; METABOLISM;

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ALZHEIMER DISEASE; ANIMALS; ANTIBODIES; HUMANS; INFLAMMATION;

EID: 84969262370     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160127112914     Document Type: Article

References (244)

1. Hardy J. A hundred years of Alzheimer’s disease research. Neuron 2006; 52: 3-13.
2. Kang J, Lemaire HG, Unterbeck A et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987; 325(6106): 733-6.
3. Kar S, Slowikowski S, Westaway D, Mount H. Interactions between -amyloid and central cholinergic neurons: implications for Alzheimer's disease. J Psychiatry Neurosci 2004; 29(6): 427-41.
4. Bednar I, Paterson D, Marutle A, et al. Selective nicotinic receptor consequences in APP(SWE) transgenic mice. Mol Cell Neurosci 2002; 20 (2): 354-65.
5. de Jong LW, Ferrarini L, van der Grond J, et al. Shape abnormalities of the striatum in Alzheimer's disease. J Alzheimers Dis 2011; 23: 49-59.
6. Reisine TD, Yamamura HI, Bird ED, Spokes E, Enna SJ. Pre-and postsynaptic neurochemical alterations in Alzheimer disease. Brain Res 1978; 159: 477-81.
7. Mousavi M, Hellström-Lindahl E, Guan ZZ, Shan KR, Ravid R, Nordberg A. Protein and mRNA levels of nicotinic receptors in brain of tobacco using controls and patients with Alzheimer's disease. Neuroscience 2003; 122 (2): 515-20.
8. Takahashi H, Mercken M, Honda T, et al. Impaired proteolytic processing of presenilin-1 in chromosome 14-linked familial Alzheimer's disease patient lymphocytes. Neurosci Lett 1999; 29: 121-4.
9. Kermer P, Liman J, Weishaupt JH, Bahr M. Neuronal apoptosis in neurodegenerative diseases: from basic research to clinical application. Neurodegener Dis 2004; 1: 9-19.
10. St George-Hyslop PH, Tanzi RE, Polinsky RJ, et al. The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science 1987; 235(4791): 885-90.
11. Haass C, Lemere CA, Capell A, et al. The Swedish mutation causes early-onset Alzheimer's disease by -secretase cleavage within the secretory pathway. Nat Med 1995; 1: 1291-6.
12. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261(5123): 921-3.
13. Bizzarro A, Marra C, Acciarri A, et al. Apolipoprotein E ɛ4 allele differentiates the clinical response to donepezil in Alzheimer’s disease. Dement Geriatr Cogn Disord 2005; 20 (4): 254-61.
14. Keverne J, Ray M. Neurochemistry of Alzheimer's disease. sychiatry 2005; 4(1): 40-2.
15. Russo P, Del Bufalo A, Frustaci A, Fini M, Cesario A. Beyond acetylcholinesterase inhibitors for treating Alzheimer's disease: α7-nAChR agonists in human clinical trials. Curr Pharm Res 2014; 20(38): 6014-21.
16. Changeux JP. The nicotinic acetylcholine receptor: the founding father of the pentameric ligand-gated ion channel superfamily. J Biol Chem 2012; 287(48): 40207-15.
17. Champtiaux N, Changeux JP. Knock-out and knock-in mice to investigate the role of nicotinic receptors in the central nervous system. Curr Drug Targets CNS Neurol Disord 2002; 1(4): 319-30.
18. Dineley KT, Pandya AA, Yakel JL. Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends Pharmacol Sci 2015; 36(2): 96-108.
19. Court J, Clementi F Distribution of nicotinic subtypes in human brain. Alzheimer Dis Assoc Disord 1995; 9(2): 6-14
20. Hellstrom-Lindahl E, Mousavi M, Zhang X, Ravid R, Nordberg A. Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Brain Res Mol Brain Res 1999; 66: 94-103.
21. Paterson D, Nordberg A Neuronal nicotinic receptors in the human brain. Progr Neurobiol 2000; 61: 75-111.
22. Posadas I, López-Hernández B, Ceña V. Nicotinic receptors in neurodegeneration. Curr Neuropharmacol 2013; 11(3): 298-314.
23. Champtiaux N, Han ZY, Bessis A, et al. Distribution and pharmacology of alpha-6 containing nicotinic acetylcholine receptors analyzed with mutant mice. J Neurosci 2002; 22: 1208-17.
24. Elgoyhen AB, Johnson DS, Boulter J, Vetter DE, Heinemann S. Alpha 9: an acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell 1994; 79(4): 705-15.
25. Dickinson JA, Kew JN, Wonnacott S. Presynaptic alpha 7-and beta 2-containing nicotinic acetylcholine receptors modulate excitatory amino acid release from rat prefrontal cortex nerve terminals via distinct cellular mechanisms. Mol Pharmacol 2008; 74(2): 348-59.
26. Huang M, Felix AR, Flood DG, et al. The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. Psychopharmacology (Berl) 2014; 231(23): 4541-51.
27. Picciotto MR, Caldarone BJ, Brunzell DH, Zachariou V, Stevens TR, King SL. Neuronal nicotinic acetylcholine receptor subunit knockout mice: physiological and behavioral phenotypes and possible clinical implications. Pharmacol Ther 2001; 92: 89-108.
28. Gotti C, Zoli M, Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 2006; 27: 482-91.
29. Wevers A, Monteggia L, Nowacki S, et al. Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alz heimer’s disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. Eur J Neurosci 1999; 11: 2551-65.
30. Wecker L, Pollock VV, Pacheco MA, Pastoor T. Nicotine-induced up regulation of α4β2 neuronal nicotinic receptors is mediated by the protein kinase C-dependent phosphorylation of α4 subunits. Neuroscience 2010; 171(1): 12-22.
31. Guan Z, Zhang X, Ravid R, Nordberg A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem 2000; 74: 237-43.
32. Zoli M, Picciotto MR, Ferrari R, Cocchi D, Changeux JP. Increased neurodegeneration during ageing in mice lacking highaffinity nicotine receptors. EMBO J 1999; 18(5): 1235-44.
33. Briggs CA, Grønlien JH, Curzon P, et al. Role of channel activation in cognitive enhancement mediated by alpha7 nicotinic acetylcholine receptors. Br J Pharmacol 2009; 158(6): 1486-94.
34. Leiser SC, Bowlby MR, Comery TA, Dunlop J. A cog in cognition: how the alpha7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol Ther 2009; 122: 302-11.
35. Deutsch SI, Burket JA, Benson AD. Targeting the α7 nicotinic acetylcholine receptor to prevent progressive dementia and improve cognition in adults with Down's syndrome. Prog Neuropsychopharmacol Biol Psychiatry 2014; 54: 131-9.
36. Wallace TL, Porter RH. Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease. Biochem Pharmacol 2011; 82(8): 891-903.
37. Nikiforuk A, Kos T, Potasiewicz A, Popik P. Positive allosteric modulation of alpha 7 nicotinic acetylcholine receptors enhances recognition memory and cognitive flexibility in rats. Eur Neuropsychopharmacol 2015; 25(8): 1300-13.
38. Granon S, Faure P, Changeux JP. Executive and social behaviours under nicotinic receptor regulation. Proc Natl Acad Sci USA 2003; 100: 9596-01.
39. Young JW, Crawford N, Kelly JS. Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur Neuropsychopharmacol 2007; 17: 145-55.
40. Roncarati R, Scali C, Comery TA, et al. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. J Pharmacol Exp Ther 2009; 329: 459-68.
41. Hernandez CM, Cortez I, Gu Z, et al. Research tool: Validation of floxed α7 nicotinic acetylcholine receptor conditional knockout mice using in vitro and in vivo approaches. J Physiol 2014; 592(Pt 15): 3201-14.
42. Carnevale D, De Simone R, Minghetti L. Microglia-neuron interaction in inflammatory and degenerative diseases: role of cholinergic and noradrenergic systems. CNS Neurol Disord Drug Targets 2007; 6(6): 388-97.
43. Niranjan R, Nath C, Shukla R. Melatonin attenuated mediators of neuroinflammation and alpha-7 nicotinic acetylcholine receptor mRNA expression in lipopolysaccharide (LPS) stimulated rat astrocytoma cells, C6. Free Radic Res 2012; 46(9): 1167-77.
44. Parri HR, Dineley KT. Nicotinic acetylcholine receptor interaction with β-amyloid: molecular, cellular, and physiological consequences. Curr Alzheimer Res 2010; 7(1): 27-39.
45. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. β-Amyloid 1-42 binds to α7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 2000; 275: 5626-32.
46. Ni R, Marutle A, Nordberg A. Modulation of α7 nicotinic acetylcholine receptor and fibrillar amyloid-β interactions in Alzheimer's disease brain. J Alzheimers Dis 2013; 33(3): 841-51.
47. Puzzo D, Privitera L, Leznik E, et al. Picomolar amyloid-β positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 2008; 28(53): 14537-45.
48. Parada E, Egea J, Romero A, del Barrio L, García AG, López MG. Poststress treatment with PNU282987 can rescue SH-SY5Y cells undergoing apoptosis via α7 nicotinic receptors linked to a Jak2/Akt/HO-1 signaling pathway. Free Radic Biol Med 2010; 49(11): 1815-21.
49. Suzuki T, Hide I, Matsubara A, et al. Microglial alpha7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role. J Neurosci Res 2006; 83(8): 1461-70.
50. Thomsen MS, Mikkelsen JD. The α7 nicotinic acetylcholine receptor ligands methyllycaconitine, NS6740 and GTS-21 reduce lipopolysaccharide-induced TNF-α release from microglia. J Neuroimmunol 2012; 251(1-2): 65-72.
51. Campbell NR, Fernandes CC, Halff AW, Berg DK. Endogenous signaling through alpha 7-containing nicotinic receptors promotes maturation and integration of adult-born neurons in the hippocampus. J Neurosci 2010; 30 (26): 8734-44.
52. Blake MG, Boccia MM, Krawczyk MC, Baratti CM. Hippocampal α7-nicotinic cholinergic receptors modulate memory reconsolidation: a potential strategy for recovery from amnesia. Neurobiol Learn Mem 2013; 106: 193-203.
53. Subramaniyan S, Heo S, Patil S, et al. A hippocampal nicotinic acetylcholine alpha 7-containing receptor complex is linked to memory retrieval in the multiple-T-maze in C57BL/6j mice. Behav Brain Res 2014; 270: 137-45.
54. Dziewczapolski G, Glogowski CM, Masliah E, Heinemann SF. Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease. J Neurosci 2009; 29(27): 8805-15.
55. Fehér A, Juhász A, Rimanóczy A, Csibri E, Kálmán J, Janka Z. Association between a genetic variant of the alpha-7 nicotinic acetylcholine receptor subunit and four types of dementia. Dement Geriatr Cogn Disord 2009; 28(1): 56-62.
56. Liou YJ, Lai IC, Hong CJ, Liu HC, Liu TY, Tsai SJ. Association analysis of the partially duplicated alpha7 nicotinic acetylcholine receptor genetic variant and Alzheimer's disease. Dement Geriatr Cogn Dis 2001; 12(5): 301-304.
57. Wang HY, Stucky A, Liu J, Shen C, Trocme-Thibierge C, Morain P. Dissociating beta-amyloid from alpha 7 nicotinic acetylcholine receptor by a novel therapeutic agent, S 24795, normalizes alpha 7 nicotinic acetylcholine and NMDA receptor function in Alzheimer's disease brain. J Neurosci 2009; 29(35): 10961-73.
58. Hernandez CM, Kayed R, Zheng H, et al. Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J Neurosci 2010; 30(7): 2442-53.
59. Lindstrom J, Neuronal nicotinic acetylcholine receptors. In: Narahashi T, Ed. Ion Channels. NY: Plenum Press 1996; vol. 4: pp. 377-90.
60. Liu Q, Huang Y, Xue F, et al. A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. J Neurosci 2009; 29(4): 918-29.
61. Virginio C, Giacometti A, Aldegheri L, Rimland JM, Terstappen GC. Pharmacological properties of rat alpha 7 nicotinic receptors expressed in native and recombinant cell systems. Eur J Pharmacol 2002; 445(3): 153-61.
62. Moretti M, Zoli M, George AA, et al. The novel α7β2-nicotinic acetylcholine receptor subtype is expressed in mouse and human basal forebrain: biochemical and pharmacological characterization. Mol Pharmacol 2014; 86(3): 306-17.
63. Murray TA, Bertrand D, Papke RL, et al. α7β2 nicotinic acetylcholine receptors assemble, function, and are activated primarily via their α7-α7 interfaces. Mol Pharmacol 2012; 81(2): 175-88.
64. Khiroug SS, Harkness PC, Lamb PW, et al. Rat nicotinic ACh receptor alpha7 and beta2 subunits co-assemble to form functional heteromeric nicotinic receptor channels. J Physiol 2002; 540(Pt 2): 425-34.
65. Azam L, Winzer-Serhan U, Leslie FM. Co-expression of alpha7 and beta2 nicotinic acetylcholine receptor subunit mRNAs within rat brain cholinergic neurons. Neuroscience 2003; 119(4): 965-77.
66. Liu Q, Xie X, Emadi S, Sierks MR, Wu J. A novel nicotinic mechanism underlies β-amyloid-induced neurotoxicity. Neuropharmacology 2015; 97: 457-63.
67. Pettit DL, Shao Z, Yakel JL. beta-Amyloid (1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci 2001; 21(1): RC120 (1-5).
68. Liu Q, Kawai H, Berg DK. beta -Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci USA 2001; 98(8): 4734-9.
69. Lilja AM, Porras O, Storelli E, Nordberg A, Marutle A. Functional interactions of fibrillar and oligomeric amyloid-ß with alpha7 nicotinic receptors in Alzheimer's disease. J Alzheimers Dis 2011; 23(2): 335-47.
70. Hernandez CM, Kayed R, Zheng H, Sweatt JD, Dineley KT. Loss of α7 nicotinic receptors enhances amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J Neurosci 2010; 30(7): 2442-53
71. Garcia-Osta A, Alberini CM. Amyloid beta mediates memory formation. Learn Mem 2009; 16(4): 267-72.
72. Jongbloed W, Bruggink KA, Kester MI, et al. Amyloid-oligomers relate to cognitive decline in Alzheimer's disease. Alzheimers Dis 2015; 45(1): 35-43.
73. Ikonomovic MD, Wecker L, Abrahamson EE, et al. Cortical α7 nicotinic acetylcholine receptor and amyloid levels in early Alzheimer disease. Arch Neurol 2009; 66(5): 646-51.
74. Kim SH, Kim YK, Jeong SJ, Haass C, Kim YH Suh YH. Enhanced release of secreted form of Alzheimer’s amyloid precursor protein from PC12 cells by nicotine. Mol Pharmacol 1997; 52: 430-6.
75. Qi XL, Nordberg A, Xiu J, Guan ZZ. The consequences of reducing expression of the alpha7 nicotinic receptor by RNA interference and of stimulating its activity with an alpha7 agonist in SHSY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimer's disease. Neurochem Int 2007; 51(6-7): 377-83.
76. Gouras GK, Almeida CG, Takahashi RH. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol Aging 2005; 26(9): 1235-44.
77. Friedricha R, Teppera K, Rönickec R, et al. Mechanism of amyloid plaque formation suggests an intracellular basis of Apathogenicity. Proc Natl Acad Sci USA 2010; 107: 1942-7.
78. Nagele RG, D'Andrea MR, Lee H, Venkataraman V, Wang HY. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res 2003; 971(2): 197-209.
79. Dineley KT, Bell KA, Bui D, Sweatt JD. beta -Amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem 2002; 277(28): 25056-61.
80. Tong M, Arora K, White MM, Nichols RA. Role of key aromatic residues in the ligand-binding domain of alpha7 nicotinic receptors in the agonist action of beta-amyloid. J Biol Chem 2011; 286(39): 34373-81.
81. Oz M, Lorke DE, Yang KH, Petroianu G. On the interaction of amyloid peptides and α7-nicotinic acetylcholine receptors in Alzheimer's disease. Curr Alzheimer Res 2013; 10 (66): 18-30.
82. Govoni S, Mura E, Racchi M, et al. Dangerous liaisons between beta-amyloid and cholinergic neurotransmission. Curr Pharm Des 2014; 20(15): 2525-38.
83. Lombardo S, Maskos U. Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment. Neuropharmacology 2015; 96(Pt B): 255-62.
84. Esposito Z, Belli L, Toniolo S, Sancesario G, Bianconi C, Martorana A. Amyloid, glutamate, excitotoxicity in Alzheimer's disease: are we on the right track? CNS Neurosci Ther 2013; 19(8): 549-55.
85. Pirttimaki TM, Codadu NK, Awni A, et al. α7 Nicotinic receptormediated astrocytic gliotransmitter release: A effects in a preclinical Alzheimer's mouse model. PLoS One 2013; 8(11): e81828.
86. Dewachter I, van Dorpe J, Spittaels K, et al. Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice. Exp Gerontol 2000; 35(6-7): 831-41.
87. Westerman MA, Cooper-Blacketer D, Mariash A, et al. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 2002; 22(5): 1858-67.
88. Lithner CU, Hedberg MM, Nordberg A. Transgenic mice as a model for Alzheimer's disease. Curr Alzheimer Res 2011; 8(8): 818-31.
89. Jones IW, Westmacott A, Chan E, et al. Alpha7 nicotinic acetylcholine receptor expression in Alzheimer's disease: receptor densities in brain regions of the APP (SWE) mouse model and in human peripheral blood lymphocytes. J Mol Neurosci 2006; 30(1-2): 83-4
90. Engidawork E, Gulesserian T, Balic N, Cairns N, Lubec G. Changes in nicotinic acetylcholine receptor subunits expresion in brain of patients with Down syndrome and Alzheimer's disease. J Neural Transm Suppl 2001; 61: 211-22.
91. Wu J, Ishikawa M, Zhang J, Hashimoto K. Brain imaging of nicotinic receptors in Alzheimer's disease. Int J Alzheimers Dis 2010; 28: 548913
92. Keverne J, Ray M. Neurochemistry of Alzheimer's disease. sychiatry 2005; 4(1): 40-2.
93. Bailey JA, Lahiri DK. Chromatographic separation of reaction products from the choline acetyltransferase and carnitine acetyltransferase assay: differential ChAT and CrAT activity in brain extracts from Alzheimer's disease versus controls. J Neurochem 2012; 122(4): 672-80.
94. Nordberg A. Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implication. Biol Psychiatry 2001; 49(3): 200-10.
95. Laursen B, Mørk A, Plath N, Kristiansen U, Bastlund JF. Impaired hippocampal acetylcholine release parallels spatial memory deficits in Tg2576 mice subjected to basal forebrain cholinergic degeneration. Brain Res 2014; 1543: 253-62.
96. Bao F, Wicklund L, Lacor PN, Klein WL, Nordberg A, Marutle A. Different -amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiol Aging 2012; 33(4): 825.e1-13.
97. Yu WF, Guan ZZ, Bogdanovic N, Nordberg A. High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. Exp Neurol 2005; 192(1): 215-25.
98. Matsumura A, Suzuki S, Iwahara N, et al. Temporal changes of CD68 and α7 nicotinic acetylcholine receptor expression in microglia in Alzheimer's disease-like mouse models. J Alzheimers Dis 2015; 44(2): 409-23.
99. Resende RR, Adhikari A. Cholinergic receptor pathways involved in apoptosis, cell proliferation and neuronal differentiation. Cell Commun Signal 2009; 7: 20-5.
100. Yu J, Huang NF, Wilson KD, et al. nAChRs mediate human embryonic stem cell-derived endothelial cells: proliferation, apoptosis, and angiogenesis. PLoS One 2009; 4(9): e7040.
101. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 2001; 21(12): 4125-33.
102. Bell KA, O'Riordan KJ, Sweatt JD, Dineley KT. MAPK recruitment by beta-amyloid in organotypic hippocampal slice cultures depends on physical state and exposure time. J Neurochem 2004; 91(2): 349-61.
103. Del Barrio L, Martín-de-Saavedra MD, Romero A, et al. Neurotoxicity induced by okadaic acid in the human neuroblastoma SH-SY5Y line can be differentially prevented by α7 and 2* nicotinic stimulation. Toxicol Sci 2011; 123(1): 193-205.
104. Gubbins EJ, Gopalakrishnan M, Li J. Alpha7 nAChR-mediated activation of MAP kinase pathways in PC12 cells. Brain Res 2010; 1328: 1-11.
105. Shimohama S. Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models. Biol Pharm Bull 2009; 32(3): 332-6.
106. Nordman JC, Kabbani N. Microtubule dynamics at the growth cone are mediated by α7 nicotinic receptor activation of a Gαq and IP3 receptor pathway. FASEB J 2014; 28(7): 2995-3006.
107. King JR, Nordman JC, Bridges SP, Lin MK, Kabbani N. Identification and characterization of a G protein-binding cluster in α7 nicotinic acetylcholine receptors. J Biol Chem 2015; 290 (33): 20060-70.
108. Razani-Boroujerdi S, Boyd RT, Davila-Garcia MI, et al. T cells express alpha7-nicotinic acetylcholine receptor subunits that require a functional TCR and leukocyte-specific protein tyrosine kinase for nicotine-induced Ca2+ response. J Immunol 2007; 179(5): 2889-98.
109. Hecker A, Mikulski Z, Lips KS, et al. Upregulation of acetylcholine synthesis and paracrine cholinergic signaling in intravascular transplant leukocytes during rejection of rat renal allografts. J Leukoc Biol 2009; 86: 13-22.
110. Chernyavsky AI, Arredondo J, Qian J, Galitovskiy V, Grando SA. Coupling of ionic events to protein kinase signaling cascades upon activation of alpha7 nicotinic receptor: cooperative regulation of alpha2-integrin expression and Rho kinase activity. J Biol Chem 2009; 284(33): 22140-8.
111. Papke RL, Bagdas D, Kulkarni AR, et al. The analgesic-like properties of the alpha7 nAChR silent agonist NS6740 is associated with non-conducting conformations of the receptor. Neuropharmacology 2015; 91: 34-42.
112. Skok MV. To channel or not to channel? Functioning of nicotinic acetylcholine receptors in leukocytes. J Leukocyte Biol 2009; 86: 1-3.
113. Enioutina EY, Myers EJ, Tvrdik P, Hoidal JR, Rogers SW, Gahring LC. The nicotinic receptor Alpha7 impacts the mouse lung response to LPS through multiple mechanisms. PLoS One 2015; 10(3): e0121128.
114. Dajas-Bailador F, Wonnacott S. Nicotinic acetylcholine receptor and the regulation of neuronal signaling. Trends Pharmacol Sci 2004; 25(6): 317-24.
115. Cui W, Hu S, Chan HH, et al. Bis(12)-hupyridone, a novel acetylcholinesterase inhibitor, protects against glutamate-induced neuronal excitotoxicity via activating α7 nicotinic acetylcholine receptor/ phosphoinositide 3-kinase/Akt cascade. Chem Biol Interact 2013; 203(1): 365-70.
116. Cucina A, Dinicola S, Coluccia P, et al. Nicotine stimulates proliferation and inhibits apoptosis in colon cancer cell lines through activation of survival pathways. J Surg Res 2012; 178 (1): 233-41.
117. Huang X, Cheng Z, Su Q, et al. Neuroprotection by nicotine against colchicine-induced apoptosis is mediated by PI3-kinase--Akt pathways. Int J Neurosci 2012; 122(6): 324-32.
118. Yu W, Mechawar N, Krantic S, Quirion R. α7 Nicotinic receptor activation reduces β-amyloid-induced apoptosis by inhibiting caspase-independent death through phosphatidylinositol 3-kinase signaling. J Neurochem 2011; 119 (4): 848-58.
119. Abbott JJ, Howlett DR, Francis PT, Williams RJ. Abeta(1-42) modulation of Akt phosphorylation via alpha7 nAChR and NMDA receptors. Neurobiol Aging 2008; 29(7): 992-1001.
120. Gergalova GL, Lykhmus OYu, Kalashnyk OM, et al. Mitochondria express α7 nicotinic acetylcholine receptors to regulate Ca2+ accumulation and cytochrome c release: study on isolated mitochondria. PLoS One 2012; 7(2): e31361.
121. Lykhmus O, Gergalova G, Koval L, Zhmak M, Komisarenko S, Skok M. Mitochondria express several nicotinic acetylcholine receptor subtypes to control various pathways of apoptosis induction. Int J Biochem Cell Biol 2014; 53: 246-52.
122. Gergalova G, Lykhmus O, Komisarenko S, Skok M. α7 Nicotinic acetylcholine receptors control cytochrome c release from isolated mitochondria through kinase-mediated pathways. Int J Biochem Cell Biol 2014; 49: 26-31.
123. Young-Collier KJ, McArdle M, Bennett JP. The dying of the light: mitochondrial failure in Alzheimer's disease. J Alzheimers Dis 2012; 28 (4): 771-81.
124. Caldeira GL, Ferreira IL, Rego AC. Impaired transcription in Alzheimer's disease: key role in mitochondrial dysfunction and oxidative stress. J Alzheimers Dis 2013; 34(1): 115-31.
125. Bartley MG, Marquardt K, Kirchhof D, Wilkins HM, Patterson D, Linseman DA. Overexpression of amyloid-β protein precursor induces mitochondrial oxidative stress and activates the intrinsic apoptotic cascade. J Alzheimers Dis 2012; 28(4): 855-68.
126. Marrero MB, Bencherif M. Convergence of alpha 7 nicotinic acetylcholine receptor-activated pathways for anti-apoptosis and antiinflammation: central role for JAK2 activation of STAT3 and NFkappaB. Brain Res 2009; 1256: 1-7.
127. Wilkins HM, Carl SM, Weber SG, et al. Mitochondrial lysates induce inflammation and Alzheimer's disease-relevant changes in microglial and neuronal cells. J Alzheimers Dis 2015; 45(1): 305-18.
128. Lu B, Kwan K, Levine YA, et al. α7 nicotinic acetylcholine receptor signaling inhibits inflammasome activation by preventing mitochondrial DNA release. Mol Med 2014; 20: 350-8.
129. Chernyavsky AI, Arredondo J, Marubio LM, Grando SA. Differential regulation of keratinocyte chemokinesis and chemotaxis through distinct nicotinic receptor subtypes. J Cell Sci 2004; 117(23): 5665-79.
130. Kummer W, Lips KS, Pfeil U. The epithelial cholinergic system of the airways. Histochem Cell Biol 2008; 130(2): 219-34.
131. Macklin KD, Maus ADJ, Pereira EFR, Albuquerque EX, Conti-Fine BM. Human vascular endothelial cells express functional nicotinic acetylcholine receptors. J Pharmacol Exp Ther 1998; 287: 435-9.
132. Koval L, Lykhmus O, Zhmak M, et al. Differential involvement of α4β2, α7 and α9α10 nicotinic acetylcholine receptors in B lymphocyte activation in vitro. Int J Biochem Cell Biol 2011; 43: 516-24.
133. Ortells M, Lunt G. Evolutionary history of the ligand-gated ion channel superfamily of receptors. Trends Neurosci 1995; 18: 121-7.
134. Bocquet N, Prado de Carvalho L, Cartaud J, et al. A prokaryotic proton-gated ion channel from the nicotinic acetylcholine receptor family. Nature 2007; 445: 116-9.
135. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405(6785): 458-62.
136. De Jonge WJ, Ulloa L. The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br J Pharmacol 2007; 151: 915-29.
137. Báez-Pagán CA, Delgado-Vélez M, Lasalde-Dominicci JA. Activation of the macrophage α7 nicotinic acetylcholine receptor and control of inflammation. J Neuroimmune Pharmacol 2015; 10(3): 468-76.
138. Ji H, Rabbi MF, Labis B, Pavlov VA, Tracey KJ, Ghia JE. Central cholinergic activation of a vagus nerve-to-spleen circuit alleviates experimental colitis. Mucosal Immunol 2014; 7(2): 335-47.
139. Truong LD, Trostel J, Garcia GE. Absence of nicotinic acetylcholine receptor α7 subunit amplifies inflammation and accelerates onset of fibrosis: an inflammatory kidney model. FASEB J 2015; 29(8): 3558-70.
140. Terrando N, Yang T, Ryu JK, et al. Stimulation of the α7 nicotinic acetylcholine receptor protects against neuroinflammation after tibia fracture and endotoxemia in mice. Mol Med 2015; 20: 667-75.
141. Tyagi E, Agrawal R, Nath C, Shukla R. Cholinergic protection via alpha7 nicotinic acetylcholine receptors and PI3K-Akt pathway in LPS-induced neuroinflammation. Neurochem Int 2010; 56(1): 135-42.
142. Egea J, Buendia I, Parada E, Navarro E, Léon R, Lopez MG. Antiinflammatory role of microglial alpha7 nAChRs and its role in neuroprotection. Biochem Pharmacol 2015; 97(4): 463-72.
143. Wee Yong V. Inflammation in neurological disorders: a help or a hindrance? Neuroscientist 2010; 16(4): 408-20.
144. Chung YC, Ko HW, Bok E, et al. The role of neuroinflammation on the pathogenesis of Parkinson's disease. BMB Rep 2010; 43(4): 225-32.
145. Blamire AM, Anthony DC, Rajagopalan B, Sibson NR, Perry VH, Styles P. Interleukin-1b-induced changes in blood-brain barrier permeability, apparent diffusion coefficient, and cerebral blood volume in the rat brain: a magnetic resonance study. J Neurosci 2000; 20(21): 8153-9.
146. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 2015; 16(6): 358-72.
147. Batoulis H, Wunsch M, Birkenheier J, Rottlaender A, Gorboulev V, Kuerten S. Central nervous system infiltrates are characterized by features of ongoing B cell-related immune activity in MP4-induced experimental autoimmune encephalomyelitis. Clin Immunol 2015; 158(1): 47-58.
148. Tuppo EE, Arias HR The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 2005; 37(2): 289-305.
149. Metcalfe MJ, Figueiredo-Pereira ME. Relationship between tau pathology and neuroinflammation in Alzheimer's disease. Mt Sinai J Med 2010; 77(1): 50-8.
150. Monson NL, Ireland SJ, Ligocki AJ, et al. Elevated CNS inflammation in patients with preclinical Alzheimer's disease. J Cereb Blood Flow Metab 2014; 34(1): 30-3.
151. Ebert S, Goos M, Rollwagen L, et al. Recurrent systemic infections with Streptococcus pneumoniae do not aggravate the course of ex perimental neurodegenerative diseases. J Neurosci Res 2010; 88(5): 1124-36.
152. Lim SL, Rodriguez-Ortiz CJ, Kitazawa M. Infection, systemic inflammation, and Alzheimer's disease. Microbes Infect 2015; 17(8): 549-56.
153. Abbayya K, Puthanakar NY, Naduwinmani S, Chidambar YS. Association between periodontitis and Alzheimer's disease. N Am J Med Sci 2015; 7(6): 241-6.
154. Gaur S, Agnihotri R. Alzheimer's disease and chronic periodontitis: is there an association? Geriatr Gerontol Int 2015; 15(4): 391-404.
155. Maheshwari P, Eslick GD. Bacterial infection and Alzheimer's disease: a meta-analysis. J Alzheimers Dis 2015; 43(3): 957-66.
156. Heneka MT, Carson MJ, Khoury JE, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol 2015; 14(4): 388-405.
157. Cheng X, Shen Y, Li R. Targeting TNF: a therapeutic strategy for Alzheimer's disease. Drug Discov Today 2014; 19(11): 1822-27.
158. Stassen M, Hültner L, Müller C, Schmitt E. Mast cells and inflammation. Arch Immunol Ther Exp (Warsz) 2002; 50(3): 179-85
159. Kinet JP. The essential role of mast cells in orchestrating inflammation. Immunol Rev 2007; 217: 5-7
160. Esposito P, Chandler N, Kandere K, et al. Corticotropin-releasing hormone and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J Pharmacol Exp Ther 2002; 303(3): 1061-6.
161. Zhuang X, Silverman AJ, Silver R. Brain mast cell degranulation regulates blood-brain barrier. J Neurobiol 1996; 31(4): 393-403.
162. Folch J, Petrov D, Ettcheto M, et al. Masitinib for the treatment of mild to moderate Alzheimer's disease. Expert Rev Neurother. 2015; 15(6): 587-96.
163. Bibi F, Yasir M, Sohrab SS, et al. Link between chronic bacterial inflammation and Alzheimer disease. CNS Neurol Disord Drug Targets 2014; 13(7): 1140-7.
164. Zhu M, Wang X, Schultzberg M, Hjorth E Differential regulation of resolution in inflammation induced by amyloid-42 and lipopolysaccharides in human microglia. J Alzheimers Dis. 2015; 43(4): 1237-50.
165. Dezsi L, Tuka B, Martos D, Vecsei L. Alzheimer's disease, astrocytes and kynurenines. Curr Alzheimer Res 2015; 12(5): 462-80.
166. Rodriguez-Vieitez E, Ni R, Gulyás B, et al. Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study. Eur J Nucl Med Mol Imaging 2015; 42(7): 1119-32.
167. Birch AM. The contribution of astrocytes to Alzheimer's disease. Biochem Soc Trans 2014; 42(5): 1316-20.
168. Rossi D. Astrocyte physiopathology: at the crossroads of intercellular networking, inflammation and cell death. Prog Neurobiol 2015; 130: 86-120.
169. Agostinho P, Cunha RA, Oliveira C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr Pharm Des 2010; 16(25): 2766-78.
170. Phillips EC, Croft CL, Kurbatskaya K, et al. Astrocytes and neuroinflammation in Alzheimer's disease. Biochem Soc Trans 2014; 42(5): 1321-5.
171. Inestrosa NC, Godoy JA, Vargas JY, et al. Nicotine prevents synaptic impairment induced by amyloid-oligomers through α7-nicotinic acetylcholine receptor activation. Neuromolecular Med 2013; 15(3): 549-69.
172. Medeiros R, Castello NA, Cheng D, et al. α7 Nicotinic receptor agonist enhances cognition in aged 3xTg-AD mice with robust plaques and tangles. Am J Pathol 2014; 184(2): 520-9.
173. Vallés AS, Borroni MV, Barrantes FJ. Targeting brain α7 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status. CNS Drugs 2014; 28(11): 975-87.
174. Steiner L, Gold M, Mengel D, Dodel R, Bach JP. The endogenous α7 nicotinic acetylcholine receptor antagonist kynurenic acid modulates amyloid--induced inflammation in BV-2 microglial cells. J Neurol Sci 2014; 344(1-2): 94-9.
175. Santos JC, de Araújo OR, Valentim IB, et al. Choline and cystine deficient diets in animal models with hepatocellular injury: evaluation of oxidative stress and expression of RAGE, TNF-α, and IL-1. Oxid Med Cell Longev 2015; 2015: 1219-25.
176. Pan ZY, Wang H. Synergistic interaction between choline and aspirin against acute inflammation induced by carrageenan and lipopolysaccharide. Int Immunopharmacol 2014; 20(1): 229-37.
177. Ash JA, Velazquez R, Kelley CM, et al. Maternal choline supplementation improves spatial mapping and increases basal forebrain cholinergic neuron number and size in aged Ts65Dn mice. Neurobiol Dis 2014; 70: 32-42.
178. Amenta F, Carotenuto A, Fasanaro AM, Rea R, Traini E. The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer's Disease) trial: interim results after two years of treatment. J Alzheimers Dis 2014; 42 (Suppl 3): S281-8.
179. Ritchie CW, Bajwa J, Coleman G, et al. Souvenaid®: a new approach to management of early Alzheimer's disease. J Nutr Health Aging 2014; 18(3): 291-9.
180. Cansev M, van Wijk N, Turkyilmaz M, Orhan F, Sijben JW, Broersen LM. A specific multi-nutrient enriched diet enhances hippocampal cholinergic transmission in aged rats. Neurobiol Aging 201; 36(1): 344-51.
181. González-Domínguez R, García A, García-Barrera T, Barbas C, Gómez-Ariza JL. Metabolomic profiling of serum in the progression of Alzheimer's disease by capillary electrophoresis-mass spectrometry. Electrophoresis 2014; 35(23): 3321-30.
182. Sezgin Z, Dincer Y. Alzheimer's disease and epigenetic diet. Neurochem Int 2014; 78: 105-16.
183. Teodoro JS, Rolo AP, Duarte FV, Simoes AM, Palmeira CM Differential alterations in mitochondrial function induced by a cholinedeficient diet: understanding fatty liver disease progression. Mitochondrion 2008; 8: 367-76.
184. Town T. Inflammation, immunity, and Alzheimer's disease. CNS Neurol Disord Drug Targets 2010; 9(2): 129-31.
185. Latta CH, Brothers HM, Wilcock DM. Neuroinflammation in Alzheimer's disease; A source of heterogeneity and target for personalized therapy. Neuroscience 2015; 302: 103-111.
186. Carrero I, Gonzalo MR, Martin B et al. Oligomers of -amyloid protein (A1-42) induce the activation of cyclooxygenase-2 in astrocytes via an interaction with interleukin-1, tumour necrosis factor-α, and a nuclear factor -B mechanism in the rat brain. Exp Neurol 2012; 236(2): 215-27.
187. Ciaramella A, Bizzoni F, Salani F, et al. Increased proinflammatory response by dendritic cells from patients with Alzheimer's disease. J Alzheimers Dis 2010; 19(2): 559-72.
188. López-González I, Schlüter A, Aso E, et al. Neuroinflammatory signals in Alzheimer disease and APP/PS1 transgenic mice: correlations with plaques, tangles, and oligomeric species. J Neuropathol Exp Neurol 2015; 74(4): 319-44.
189. Zelcer N, Khanlou N, Clare R Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc Natl Acad Sci USA 2007; 104(25): 10601-6.
190. Tan ZS, Seshadri S Inflammation in the Alzheimer's disease cascade: culprit or innocent bystander? Alzheimers Res Ther 2010; 2: 2-6.
191. Rontu R, Ojala P, Hervonen A, et al. Apolipoprotein E genotype is related to plasma levels of C-reactive protein and lipids and to longevity in nonagenarians. Clin Endocrinol (Oxf) 2006; 64(3): 265-70.
192. Hall JR, Wiechmann AR, Johnson LA, et al. The impact of APOE status on relationship of biomarkers of vascular risk and systemic inflammation to neuropsychiatric symptoms in Alzheimer's disease. J Alzheimers Dis 2014; 40(4): 887-96.
193. Marchese M, Cowan D, Head E, et al. Autoimmune manifestations in the 3xTg-AD model of Alzheimer's disease. J Alzheimers Dis 2014; 39(1): 191-210.
194. Lykhmus, Voytenko L, Koval, et al. α7 Nicotinic acetylcholine receptor-specific antibody induces inflammation and amyloid 42 accumulation in the mouse brain to impair memory. PLoS One 2015; 10(3): e0122706.
195. Lykhmus O, Gergalova G, Zouridakis M, Tzartos S, Komisarenko S, Skok M. Inflammation decreases the level of alpha7 nicotinic acetylcholine receptors in the brain mitochondria and makes them more susceptible to apoptosis induction. Int Immunopharmacol 2015; 29(1): 148-51.
196. Lykhmus OYu, Koval LM, Skok MV, et al. Antibodies against extracellular domains of alpha4 and alpha7 subunits alter the levels of nicotinic receptors in the mouse brain and affect memory: possible relevance to Alzheimer pathology. J Alzheimers Dis 2011; 24: 693-704.
197. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 2001; 21: 7463-73.
198. Stauderman KA, Mahaffy LS, Akong M, et al. Characterization of human recombinant neuronal nicotinic acetylcholine receptor subunit combinations alpha2beta4, alpha3beta4 and alpha4beta4 stably expressed in HEK293 cells. J Pharmacol Exp Ther 1998; 284: 777-89.
199. Lax P, Fucile S, Eusebi F. Ca(2+) permeability of human heteromeric nAChRs expressed by transfection in human cells. Cell Calcium 2002; 32(2): 53-8.
200. Arshavsky YuI. Why Alzheimer’s disease starts with a memory impairment: neurophysiological insight. J Alzheimer Dis 2010; 20(1): 5-16.
201. Kondo Y, Tachikawa E, Ohtake S, et al. Inflammatory cytokines decrease the expression of nicotinic acetylcholine receptor during the cell maturation. Mol Cell Biochem 2010; 333(1-2): 57-64.
202. Khairallah MI, Kassem LA, Yassin NA, El Din MA, Zekri M, Attia M. The hematopoietic growth factor "erythropoietin" enhances the therapeutic effect of mesenchymal stem cells in Alzheimer's disease. Pak J Biol Sci 2014; 17(1): 9-21.
203. Maher A, El-Sayed NS, Breitinger HG, Gad MZ. Overexpression of NMDAR2B in an inflammatory model of Alzheimer's disease: modulation by NOS inhibitors. Brain Res Bull 2014; 109: 109-16.
204. El-Sayed NS, Bayan Y. Possible role of resveratrol targeting estradiol and neprilysin pathways in lipopolysaccharide model of Alzheimer disease. Adv Exp Med Biol 2015; 822: 107-18.
205. Hauss-Wegrzyniak B, Dobrzanski P, Stoehr JD, Wenk GL. Chronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer's disease. Brain Res 1998; 780(2): 294-303.
206. Lykhmus O, Koval L, Pavlovych S, et al. Functional effects of antibodies against non-neuronal nicotinic acetylcholine receptors. Immunol Lett 2010; 128: 68-73.
207. Kalashnyk OM, Lykhmus OYU, Oliinyk OA, Komisarenko SV, Skok MV. α7 nAChR-specific antibodies stimulate proinflammatory reaction in human astrocytes through p38-dependent pathway. Int Immunopharmacol 2014; 23(2): 475-9.
208. Liu A, Gong P, Hyun SW, et al. TRAF6 protein couples Toll-like receptor 4 signaling to Src family kinase activation and opening of paracellular pathway in human lung microvascular endothelia. J Biol Chem 2012; 287(20): 16132-45.
209. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11(5): 373-84.
210. Exley R, Cragg SJ. Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission. Br J Pharmacol 2008; 153(1): 283-97.
211. Selden N, Mesulam MM, Geula C. Human striatum: the distribution of neurofibrillary tangles in Alzheimer's disease. Brain Res 1994; 648: 327-31.
212. Broadbent NJ, Gaskin S, Squire LR, Clark RE. Object recognition memory and the rodent hippocampus. Learn Mem 2009; 17: 794-800.
213. Knowlton BJ, Mangels JA, Squire LR. A neostriatal habit learning system in humans. Science 1996; 273: 1399-402.
214. Doeller CF, King JA, Burgess N. Parallel striatal and hippocampal systems for landmarks and boundaries in spatial memory. Proc Natl Acad Sci USA 2008; 105: 5915-20.
215. Lansink CS, Goltstein PM, Lankelma JV, McNaughton BL, Pennartz CM. Hippocampus leads ventral striatum in replay of placereward information. PLoS Biol 2009; 7(8): e1000173.
216. Volpina OM, Volkova TD, Titova MA, et al. New approaches to the immunotherapy of Alzheimer’s disease with the synthetic fragments of α7 subunit of the acetylcholine receptor. Russian J Bioorg Chem 2008; 34(1): 43-8.
217. Kamynina AV, Volpina OM, Medvinskaya NI, et al. Vaccination with peptide 173-193 of acetylcholine receptor alpha7-subunit prevents memory loss in olfactory bulbectomized mice. J Alzheimers Dis 2011; 21(1): 249-61.
218. Bufler J, Kahlert S, Tzartos S, Toyka KV, Maelicke A, Franke C. Activation and blockade of mouse muscle nicotinic channels by antibodies directed against the binding site of the acetylcholine receptor. J Physiol 1996; 492(Pt 1): 107-14.
219. Faust TW, Chang EH, Kowal C, et al. Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc Natl Acad Sci USA 2010; 107(43): 18569-74.
220. Chernyavsky A, Chen Y, Wang PH, Grando SA. Pemphigus vulgaris antibodies target the mitochondrial nicotinic acetylcholine receptors that protect keratinocytes from apoptolysis. Int Immunopharmacol 2015; 29(1): 76-80.
221. Kamynina AV, Holmström KM, Koroev DO, Volpina OM, Abramov AY. Acetylcholine and antibodies against the acetylcholine receptor protect neurons and astrocytes against beta-amyloid toxicity. Int J Biochem Cell Biol 2013; 45(4): 899-907.
222. Lleo A, Invernizzi P, Gao B, Podda M, Gershwin ME. Definition of human autoimmunity-autoantibodies versus autoimmune disease. Autoimmun Rev 2010; 9(5): A259-66.
223. Diamond B, Volpe BT. Antibodies and brain disease: a convergence of immunology and physiology. PLoS Med 2006; 3 (12): e498.
224. Kowal C, Degiorgio LA, Lee JY, et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci USA 2006; 103: 19854-9.
225. Vincent A, Irani SR, Lang B The growing recognition of immunotherapy-responsive seizure disorders with autoantibodies to specific neuronal proteins. Curr Opin Neurol 2010; 23(2): 144-50.
226. Papachroni KK, Ninkina N, Papapanagiotou A, et al. Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem 2007; 101(3): 749-56.
227. Needham E, Zandi MS. Recent advances in the neuroimmunology of cell-surface CNS autoantibody syndromes, Alzheimer's disease, traumatic brain injury and schizophrenia. J Neurol 2014; 261(10): 2037-42.
228. Neff F, Wei X, Nölker C, Bacher M, Du Y, Dodel R. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun Rev 2008; 7(6): 501-7.
229. Colasanti T, Barbati C, Rosano G, Malorni W, Ortona E. Autoantibodies in patients with Alzheimer's disease: pathogenetic role and potential use as biomarkers of disease progression. Autoimmun Rev 2010; 9(12): 807-11.
230. Karczewski P, Haase H, Hempel P, Bimmler M. Agonistic antibody to the alpha1-adrenergic receptor mobilizes intracellular calcium and induces phosphorylation of a cardiac 15-kDa protein. Mol Cell Biochem 2010; 333(1-2): 233-42.
231. Vacirca D, Delunardo F, Matarrese P, et al. Autoantibodies to the adenosine triphosphate synthase play a pathogenetic role in Alzheimer's disease. Neurobiol Aging 2012; 33(4): 753-66.
232. Storace D, Cammarata S, Borghi R, et al. Elevation of {beta}-amyloid 1-42 autoantibodies in the blood of amnestic patients with mild cognitive impairment. Arch Neurol 2010; 67(7): 867-72.
233. Weiner HL, Lemere CA, Maron R, et al. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 2000; 48(4): 567-79.
234. Agadjanyan MG, Petrovsky N, Ghochikyan A. A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease. Alzheimers Dement 2015; 11(10): 1246-59.
235. Lambracht-Washington D, Rosenberg RN. Anti-amyloid beta to tau-based immunization: Developments in immunotherapy for Alzheimer disease. Immunotargets Ther 2013; 2013(2): 105-14.
236. Jayam Trouth, A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: a review. Autoimmune Dis 2012; 2012; 874680.
237. Grando SA. Autoimmunity to keratinocyte acetylcholine receptors in pemphigus. Dermatology 2000; 201(4): 290-5.
238. Koval L, Lykhmus O, Kalashnyk O, et al. The presence and origin of autoantibodies against alpha4 and alpha7 nicotinic acetylcholine receptors in the human blood: possible relevance to Alzheimer pathology. J Alzheimers Dis 2011; 25: 747-61.
239. Schwartz-Albiez R, Monteiro RC, Rodriguez M, Binder CJ, Shoenfeld Y. Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation. Clin Exp Immunol 2009; 158 (1): 43-50.
240. Del Valle J, Duran-Vilaregut J, Manich G, et al. Time-course of blood-brain barrier disruption in senescence-accelerated mouse prone 8 (SAMP8) mice. Int J Dev Neurosci 2009; 27 (1): 47-52.
241. Jaeger LB, Dohgu S, Sultana R, et al. Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer's disease. Brain Behav Immun 2009; 23(4): 507-17.
242. Michaud M, Balardy L, Moulis G, et al. Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc 2013; 14(12): 877-82.
243. Alcolea D, Martínez-Lage P, Sánchez-Juan P, et al. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology 2015; 85(7): 626-33.
244. Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009; 73(10): 768-74.